Curated News
By: NewsRamp Editorial Staff
June 03, 2025
Quantum BioPharma Denies RTO Rumors, Details Unbuzzd Stake
TLDR
- Quantum BioPharma clarifies no name change or RTO with Unbuzzd, maintaining its strategic investments and royalties, offering investors clear advantages in biopharmaceutical innovations.
- Quantum BioPharma detailed its financial and operational separateness from Unbuzzd, including shareholdings, royalty agreements, and a $1.3 million loan, amidst social media misinformation.
- Quantum BioPharma's commitment to treating neurodegenerative and metabolic disorders through innovative biotech solutions promises a healthier future for affected individuals worldwide.
- Quantum BioPharma, holding significant stakes in Unbuzzd, navigates through misinformation while advancing in biopharmaceutical research and strategic investments.
Impact - Why it Matters
This clarification from Quantum BioPharma is crucial for investors and stakeholders to distinguish between the operations and financial engagements of Quantum and Unbuzzd. Misinformation can lead to unwarranted volatility in stock prices and investor confusion. Understanding the distinct yet interconnected relationship between these entities provides clarity on Quantum's investment strategy and its potential impact on the biopharmaceutical sector, especially in treatments for neurodegenerative and metabolic disorders.
Summary
Quantum BioPharma (NASDAQ: QNTM) has officially clarified misinformation circulating on social media and stock trading platforms about a supposed name change and reverse takeover (RTO) with Unbuzzd Wellness Inc. The company confirmed it has not undergone a name change to unbuzzd and is not engaged in any RTO transaction. Despite being Unbuzzd's largest shareholder and debt holder, Quantum BioPharma maintains its separate identity, holding 200 million shares of Unbuzzd, a 7% royalty agreement on revenue up to $250 million, and a warrant to increase its stake to 25%. Additionally, Quantum has loaned Unbuzzd $1.3 million at a 10% interest rate over three years. Unbuzzd, under the leadership of industry veterans John Duffy and Gerry David, is gearing up for a potential IPO, with PCAOB audits being conducted by MNP LLP. Quantum also disclosed a forthcoming $20,930 debt settlement with two vendors, expected to be finalized in early June.
Quantum BioPharma is a biopharmaceutical firm focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its subsidiary, Lucid Psycheceuticals Inc., is advancing Lucid-MS, a patented compound aimed at addressing myelin degradation in multiple sclerosis. Quantum also retains a significant stake in Celly Nutrition Corp., the company behind the OTC version of UNBUZZD(TM), and continues to explore pharmaceutical applications of similar products. For more details, visit the full press release at https://ibn.fm/XayYB.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Denies RTO Rumors, Details Unbuzzd Stake
